Global burden of COPD: risk factors, prevalence, and future trends

被引:1786
作者
Mannino, David M.
Buist, A. Sonia
机构
[1] Univ Kentucky, Coll Publ Hlth, Dept Prevent Med & Environm Hlth, Lexington, KY 40536 USA
[2] Oregon Hlth & Sci Univ, Dept Med Pulm & Crit Care Med, Portland, OR USA
关键词
D O I
10.1016/S0140-6736(07)61380-4
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Chronic obstructive pulmonary disease (COPD) continues to be an important cause of morbidity, mortality, and health-care costs worldwide. It is a global health issue, with cigarette smoking being an important risk factor universally; other factors, such as exposure to indoor and outdoor air pollution, occupational hazards, and infections, are also important. As the global population ages, the burden of COPD will increase in years to come. Prevalence estimates of the disorder show considerable variability across populations, suggesting that risk factors can affect populations differently. Other advances in our understanding of COPD are increased recognition of the importance of comorbid disease, identification of different COPD phenotypes, and understanding how factors other than lung function affect outcome in our patients. The challenge we will all face in the next few years will be implementation of cost-effective prevention and management strategies to stem the tide of this disease and its cost.
引用
收藏
页码:765 / 773
页数:9
相关论文
共 82 条
[1]
Agusti Alvar G N, 2005, Proc Am Thorac Soc, V2, P367, DOI 10.1513/pats.200504-026SR
[2]
[Anonymous], 2006, HLTH CONS INV EXP TO
[3]
Anthonisen N R, 2005, Can Respir J, V12, P69
[4]
The British hypothesis revisited [J].
Anthonisen, NR .
EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (05) :657-658
[5]
EFFECTS OF SMOKING INTERVENTION AND THE USE OF AN INHALED ANTICHOLINERGIC BRONCHODILATOR ON THE RATE OF DECLINE OF FEV(1) - THE LUNG HEALTH STUDY [J].
ANTHONISEN, NR ;
CONNETT, JE ;
KILEY, JP ;
ALTOSE, MD ;
BAILEY, WC ;
BUIST, AS ;
CONWAY, WA ;
ENRIGHT, PL ;
KANNER, RE ;
OHARA, P ;
OWENS, GR ;
SCANLON, PD ;
TASHKIN, DP ;
WISE, RA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (19) :1497-1505
[6]
Epidemiology of chronic obstructive pulmonary disease [J].
Antó, JM ;
Vermeire, P ;
Vestbo, J ;
Sunyer, J .
EUROPEAN RESPIRATORY JOURNAL, 2001, 17 (05) :982-994
[7]
Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase [J].
Barnes, PJ ;
Ito, K ;
Adcock, IM .
LANCET, 2004, 363 (9410) :731-733
[8]
Smokers with airway obstruction are more likely to quit smoking [J].
Bednarek, M. ;
Gorecka, D. ;
Wielgomas, J. ;
Czajkowska-Malinowska, M. ;
Regula, J. ;
Mieszko-Filipczyk, G. ;
Jasionowicz, M. ;
Bijata-Bronisz, R. ;
Lempicka-Jastrzebska, M. ;
Czajkowski, M. ;
Przybylski, G. ;
Zielinski, J. .
THORAX, 2006, 61 (10) :869-873
[9]
International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study [J].
Buist, A. Sonia ;
McBurnie, Mary Ann ;
Vollmer, William M. ;
Gillespie, Suzanne ;
Burney, Peter ;
Mannino, David M. ;
Menezes, Ana M. B. ;
Sullivan, Sean D. ;
Lee, Todd A. ;
Weiss, Kevin B. ;
Jensen, Robert L. ;
Marks, Guy B. ;
Gulsvik, Amund ;
Nizankowska-Mogilnicka, Ewa .
LANCET, 2007, 370 (9589) :741-750
[10]
What have we learned from large drug treatment trials in COPD? [J].
Calverley, Peter M. A. ;
Rennard, Stephen I. .
LANCET, 2007, 370 (9589) :774-785